Human papillomavirus is responsible for 95% of cervical tumours. Since 2006, several vaccines have been licensed that can prevent most cases. In Spain, the autonomous communities […]

fundacionidis.com The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the […]

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is […]

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One […]

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. larazon.es Developing and producing new medicines for society is both […]

The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. Farmaindustria.es The drive for clinical research in Primary […]

Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and […]

Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. Farmaindustria.es “The proposed Regulation for […]

Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of […]

Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in […]

The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For […]

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply […]

The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in […]

This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. […]

On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments […]

The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make […]

elglobal.es   In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of […]

Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% […]

In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data […]

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, […]

The vast majority of them are aimed at modifying the course of the disease, according to an Iqvia report on the future of R&D. In Spain […]

Only 7.5% are carried out in health centres. In order to alleviate this situation, Farmaindustria has presented a programme to promote them in outpatient clinics. Source: […]